试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-12
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
编号:NCT05654870登记状态:提前终止企业 / 申办者:Neurocrine Biosciences
药物 / 成分:Valbenazine、Placebo
登记的停止原因(原文):Study ATS3020 was closed due to business reasons. Neurocrine Biosciences will continue to conduct study ATS3019 (NCT05110157). There were no unexpected safety findings for this compound that motivated the decision.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-12
Patiromer Trial in CKD Stage IIIB to V
编号:NCT05786469登记状态:提前终止企业 / 申办者:Mario Negri Institute for Pharmacological Research
药物 / 成分:Veltassa Oral Powder Product、Placebo
登记的停止原因(原文):Unable to reach planned study sample size due to increased patient failure to meet inclusion criteria.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-08
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
编号:NCT01318642登记状态:提前终止企业 / 申办者:NantBioScience, Inc.
药物 / 成分:Gemcitabine、AMG 479、Placebo
登记的停止原因(原文):NCT01318642: Planned independent DMC Interim review: ended for futility
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-08
A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
编号:NCT03118713登记状态:提前终止企业 / 申办者:Astellas Pharma Korea, Inc.
药物 / 成分:metformin、ipragliflozin、glimepiride
登记的停止原因(原文):Business decision due to enrollment challenges
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-08
Long Term Safety Observation of Crizotinib in Chinese NSCLC Population
编号:NCT03672643登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:Crizotinib
登记的停止原因(原文):The trial is terminated based on business decision, not due to safety concerns or regulatory requirements.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-08
Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
编号:NCT04060849登记状态:提前终止企业 / 申办者:Fred Hutchinson Cancer Center
药物 / 成分:Nozin、Best Practice
登记的停止原因(原文):The study was closed to accrual according to the Fred Hutch/University of Washington/Seattle Children's Consortium low accrual institutional policy.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-08
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
编号:NCT04060862登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Ipatasertib、Placebo、Palbociclib、Fulvestrant
登记的停止原因(原文):The decision to not open the Phase III portion was based on a strategic sponsor decision and not driven by any safety concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-08
Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG
编号:NCT04162600登记状态:提前终止企业 / 申办者:University of Oxford
药物 / 成分:ChAdOx2 RabG、Inactivated Rabies Vaccine、ChAdOx2 RabG、ChAdOx2 RabG
登记的停止原因(原文):Since acceptable safety, tolerability, and immunogenicity was demonstrated at the highest dose tested (group 3, fully recruited), there was no scientific or ethical justification to recruit more participants into the mid-dose group (group 2).
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-08
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema
编号:NCT04292912登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:GSK2798745
登记的停止原因(原文):The study was terminated as the study met the prespecified threshold for futility of less than (\<) 20 percentage (%), based on interim analysis (IA).
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-08
Anti-inflammatory Effects of Simvastatin
编号:NCT04638400登记状态:提前终止企业 / 申办者:paresh Dandona
药物 / 成分:Simvastatin 40mg、Ezetimibe 10mg
登记的停止原因(原文):Lack of recruitment- Fellow responsible for study graduated
查看官方原始记录 ↗